Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.

Ngo mentions that availability of Wegovy could be difficult because the drug is so popular. “Supply chain issues may arise from time to time. Novo Nordisk is actively working to ramp up ...

the main ingredient in Ozempic and Wegovy, have led to at least 100 hospitalizations and 10 deaths. CEO Lars Fruergaard ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 ...

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply ...

Since Wegovy is a prescription medication, your insurance coverage may affect your ability to get the drug at an affordable cost. The status of the supply chain can also determine how accessible ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...

On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Sales of Novo Nordisk’s obesity drug Wegovy were 81% higher in the third quarter of 2024 than the same period last year amid loosening supply constraints and broader insurance coverage ...